The purpose of this systematic review is to assess and summarise the efficacy and safety of tadalafil alone or in combination with tamsulosin in the treatment of lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), and erectile dysfunction (ED). According to retrieved research, daily tadalafil, specifically 5 mg, appears to be both safe and effective in treating LUTS/BPH and ED when compared to placebo or tamsulosin. The combination of daily tadalafil 5 mg and tamsulosin 0.4 mg improves LUTS better than either alone, but at a higher, but tolerable and tolerated, incidence of side effects. In individuals previously treated with tamsulosin or tadalafil in combination, the improvement in LUTS remains significant as compared to baseline.
Tadalafil 5 mg should be regarded as a first-line therapy option for people suffering from LUTS/BPH and ED. Evidence suggests that it has a great tolerance, safety, and efficacy profile whether used alone or in combination with tamsulosin. Combination treatment has been shown to be more effective in relieving LUTS while still retaining sexual function. The subsequent transition to monotherapy allows for the preservation of LUTS alleviation, whereas tadalafil is only capable of preserving ED improvement. The findings reinforce the evidence for a more customised and modular LUTS healthcare system.